{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:01:47Z","timestamp":1784764907650,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.biopha.2024.117414","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T01:58:51Z","timestamp":1725933531000},"page":"117414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["New drug combination regimen based on pharmacokinetic characteristics\u2014Erdafitinib combined with sertraline or duloxetine"],"prefix":"10.1016","volume":"179","author":[{"given":"Xiao-dan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-shan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-hao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-chao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-huan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9985-3852","authenticated-orcid":false,"given":"Jian-chang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-guo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2024.117414_bib1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117414_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"B.L.C.S. Group, Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.biopha.2024.117414_bib3","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","article-title":"Multifunctional nanoparticle-mediated combining therapy for human diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.117414_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040669","article-title":"Drug combination in cancer treatment-from cocktails to conjugated combinations","volume":"13","author":"Gilad","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2024.117414_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.biopha.2024.117414_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117414_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-021-01471-8","article-title":"Imipenem\/cilastatin\/relebactam: a review in gram-negative bacterial infections","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijantimicag.2008.02.004","article-title":"Rational antibiotic therapy and the position of ampicillin\/sulbactam","volume":"32","author":"Lode","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"21","key":"10.1016\/j.biopha.2024.117414_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"T.C. Investigators, erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2024.117414_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117414_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/psp4.12682","article-title":"Prediction of the drug-drug interaction potential of the alpha1-acid glycoprotein bound, CYP3A4\/CYP2C9 metabolized oncology drug, erdafitinib","volume":"10","author":"De Zwart","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13318-019-00581-9","article-title":"Effect of fluconazole and itraconazole on the pharmacokinetics of erdafitinib in healthy adults: a randomized, open-label, drug-drug interaction study","volume":"45","author":"Poggesi","year":"2020","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"10.1016\/j.biopha.2024.117414_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.749169","article-title":"The Effect of posaconazole and isavuconazole on the pharmacokinetics of erdafitinib in beagle dogs by UPLC-MS\/MS","volume":"12","author":"Ruan","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2024.117414_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109700","article-title":"Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro","volume":"350","author":"Han","year":"2021","journal-title":"Chem. Biol. Inter."},{"issue":"3","key":"10.1016\/j.biopha.2024.117414_bib16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00253-015-7039-6","article-title":"Denitrifying sulfide removal process on high-salinity wastewaters in the presence of Halomonas sp","volume":"100","author":"Liu","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"21","key":"10.1016\/j.biopha.2024.117414_bib17","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/bioinformatics\/btr507","article-title":"FLASH: fast length adjustment of short reads to improve genome assemblies","volume":"27","author":"Magoc","year":"2011","journal-title":"Bioinformatics"},{"issue":"10","key":"10.1016\/j.biopha.2024.117414_bib18","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/nmeth.2604","article-title":"UPARSE: highly accurate OTU sequences from microbial amplicon reads","volume":"10","author":"Edgar","year":"2013","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.biopha.2024.117414_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","article-title":"PICRUSt2 for prediction of metagenome functions","volume":"38","author":"Douglas","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2024.117414_bib20","article-title":"Psychological distress and mental health care utilization among Black survivors of adolescent and young adult cancer","author":"Choi","year":"2024","journal-title":"Cancer"},{"issue":"Pt 2","key":"10.1016\/j.biopha.2024.117414_bib21","article-title":"Metabolic activation and cytochrome P450 inhibition of piperlonguminine mediated by CYP3A4","volume":"268","author":"Chi","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1080\/14756366.2022.2076089","article-title":"Models of enzyme inhibition and apparent dissociation constants from kinetic analysis to study the differential inhibition of aldose reductase","volume":"37","author":"Balestri","year":"2022","journal-title":"J. Enzym. Inhib. Med Chem."},{"issue":"2","key":"10.1016\/j.biopha.2024.117414_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FPC.0000000000000392","article-title":"PharmGKB summary: sertraline pathway, pharmacokinetics","volume":"30","author":"Huddart","year":"2020","journal-title":"Pharm. Genom."},{"issue":"4","key":"10.1016\/j.biopha.2024.117414_bib24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00004714-200008000-00007","article-title":"Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes","volume":"20","author":"Hemeryck","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3458.2001.tb00188.x","article-title":"The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders","volume":"7","author":"MacQueen","year":"2001","journal-title":"CNS Drug Rev."},{"issue":"3","key":"10.1016\/j.biopha.2024.117414_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/mcp.2003.28","article-title":"Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers","volume":"73","author":"Skinner","year":"2003","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cpt.1768","article-title":"A scoping review of the evidence behind cytochrome P450 2D6 isoenzyme inhibitor classifications","volume":"108","author":"Cicali","year":"2020","journal-title":"Clin. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.117414_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Duloxetine: clinical pharmacokinetics and drug interactions","volume":"50","author":"Knadler","year":"2011","journal-title":"Clin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.117414_bib29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cpt.1409","article-title":"Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy","volume":"106","author":"Brown","year":"2019","journal-title":"Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.117414_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40262-020-00926-7","article-title":"Volume of distribution is unaffected by metabolic drug-drug interactions","volume":"60","author":"Sodhi","year":"2021","journal-title":"Clin. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2024.117414_bib32","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.117414_bib33","article-title":"The causal relationship between gut microbiota and bone mineral density: a Mendelian randomization study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.biopha.2024.117414_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11092249","article-title":"Research on pachymaran to ameliorate CsA-induced immunosuppressive lung injury by regulating microflora metabolism","volume":"11","author":"Ye","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.biopha.2024.117414_bib35","article-title":"Bifidobacterium longum S3 alleviates loperamide-induced constipation by modulating intestinal acetic acid and stearic acid levels in mice","author":"Zhang","year":"2024","journal-title":"Food Funct."},{"issue":"2","key":"10.1016\/j.biopha.2024.117414_bib36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1039\/D3FO03733A","article-title":"Ferrous-sucrose complex supplementation regulates maternal plasma metabolism and the fecal microbiota composition and improves neonatal immunity and placental glucose transportation by activating the EGF\/PI3K\/AKT signaling pathways in sows","volume":"15","author":"Dong","year":"2024","journal-title":"Food Funct."},{"issue":"1","key":"10.1016\/j.biopha.2024.117414_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40168-024-01804-1","article-title":"Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity","volume":"12","author":"Then","year":"2024","journal-title":"Microbiome"},{"key":"10.1016\/j.biopha.2024.117414_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2020.612875","article-title":"Modulation of gut microbiota and oxidative status by beta-carotene in late pregnant sows","volume":"7","author":"Yuan","year":"2020","journal-title":"Front. Nutr."},{"key":"10.1016\/j.biopha.2024.117414_bib39","doi-asserted-by":"crossref","first-page":"1387957","DOI":"10.3389\/fmicb.2024.1387957","article-title":"Hybridization alters red deer gut microbiome and metabolites","volume":"15","author":"Wei","year":"2024","journal-title":"Front. Microbiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222401299X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222401299X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:15:02Z","timestamp":1784762102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222401299X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":39,"alternative-id":["S075333222401299X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117414","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drug combination regimen based on pharmacokinetic characteristics\u2014Erdafitinib combined with sertraline or duloxetine","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117414"}}